Our current studies are the first to our knowledge to show that targeting TREM-1 using ligand-independent peptide inhibitors prevents and reverses pathological skin fibrosis in mice and represents a potential antifibrotic strategy for the treatment of fibrosis in patients with SSc. This evidence concerns the gene TREM1 and systemic sclerosis.